AltheaDx, Inc. Sustainability Profile
AltheaDx, Inc., a prominent player in the genomic testing industry, is headquartered in the United States. Founded in 2011, the company has established itself as a leader in precision medicine, focusing on pharmacogenomics and molecular diagnostics. AltheaDx's innovative products, including its proprietary IDgenetix® platform, provide healthcare professionals with critical insights into patient-specific drug responses, enhancing personalised treatment plans. With a commitment to advancing patient care, AltheaDx has achieved significant milestones, including partnerships with leading healthcare institutions and a growing presence in major operational regions across North America. The company's unique approach to integrating genetic data into clinical practice positions it at the forefront of the evolving landscape of personalised medicine, making it a trusted resource for clinicians and patients alike.
DitchCarbon Score
How does AltheaDx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AltheaDx, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AltheaDx, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Castle Biosciences, Inc., which may influence its climate commitments and reporting practices. As of now, AltheaDx has not established any documented reduction targets or initiatives related to carbon emissions. There are no Science-Based Targets Initiative (SBTi) reduction targets or climate pledges reported, suggesting a lack of formalised commitments to reduce greenhouse gas emissions at this time. Given the absence of direct emissions data and reduction initiatives, it is essential to monitor AltheaDx's future climate strategies and commitments, particularly as they may align with broader industry trends and the sustainability goals of their parent company, Castle Biosciences, Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 24,130 |
| Scope 2 | 730,950 |
| Scope 3 | - |
How Carbon Intensive is AltheaDx, Inc.'s Industry?
How Carbon Intensive is AltheaDx, Inc.'s Location?
AltheaDx, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AltheaDx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.